Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Sapien 3 Valve Approved in Europe for Low-Risk Patients

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

FDA Expands TAVR Indication to Low-Risk Patients

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

FDA Approves Lotus Edge, Ushering Third Device Into US Market

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

April 24, 2019

News Industry News

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

April 23, 2019

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

News Daily News

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

January 02, 2019

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

June 05, 2017

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.